Transplantation proceedings · 2026
Daratumumab in Antibody-Mediated Rejection After Kidney Transplantation: Mechanistic Rationale, Published Clinical Experience, and a Single-Center Case Series.
СтатьяКлинический случайОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sridhara Srilekha, Cho Elizabeth L, Nelson Joelle E, Khamash Hasan A, Alasfar Sami, Siegel Ruby J, Mour Girish K, Budhiraja Pooja, Kodali Lavanya, Tanriover Bekir, Abu Jawdeh Bassam G
Аннотация
BACKGROUND: Antibody-mediated rejection (AMR), driven by donor-specific antibodies (DSAs), remains a major cause of kidney allograft dysfunction. Conventional therapies reduce circulating antibodies and target precursor B cells but often fail to eliminate long-lived plasma cells, contributing to persistent or recurrent DSAs. CD38 is highly expressed on antibody-secreting cells, making it a selective therapeutic target for plasma cell depletion. Daratumumab, a fully human anti-CD38 IgG1κ monoclonal antibody, mediates depletion of CD38-expressing cells.
OBJECTIVES: Summarize the mechanistic rationale of daratumumab, review published experience with daratumumab in kidney transplantation, and describe a single-center experience using daratumumab for early, refractory AMR.
METHODS: We conducted a narrative review of CD38 targeting in AMR and evaluated a retrospective single-center case series of kidney transplant recipients (KTRs) treated with daratumumab after suboptimal response to institutional first-line therapy. Kidney allograft biopsy findings, DSA trajectories, and renal function parameters were trended during follow-up. This study complied with the Declaration of Helsinki and the Declaration of Istanbul; no organs were procured from prisoners or paid donors.
RESULTS: Two highly sensitized KTRs developed early acute AMR with persistent DSAs despite first-line therapies. Repeat biopsies demonstrated chronic active AMR (Patient 1) and ongoing/smoldering AMR (Patient 2). Subcutaneous daratumumab was initiated in both patients and there was a durable reduction in DSAs and stabilization or improvement in allograft function.
CONCLUSIONS: Daratumumab may serve as an adjunctive option for refractory AMR with persistent DSAs by targeting plasma cell-mediated alloantibody production. Prospective studies are required to define optimal dosing, timing, safety monitoring, and patient selection.
OBJECTIVES: Summarize the mechanistic rationale of daratumumab, review published experience with daratumumab in kidney transplantation, and describe a single-center experience using daratumumab for early, refractory AMR.
METHODS: We conducted a narrative review of CD38 targeting in AMR and evaluated a retrospective single-center case series of kidney transplant recipients (KTRs) treated with daratumumab after suboptimal response to institutional first-line therapy. Kidney allograft biopsy findings, DSA trajectories, and renal function parameters were trended during follow-up. This study complied with the Declaration of Helsinki and the Declaration of Istanbul; no organs were procured from prisoners or paid donors.
RESULTS: Two highly sensitized KTRs developed early acute AMR with persistent DSAs despite first-line therapies. Repeat biopsies demonstrated chronic active AMR (Patient 1) and ongoing/smoldering AMR (Patient 2). Subcutaneous daratumumab was initiated in both patients and there was a durable reduction in DSAs and stabilization or improvement in allograft function.
CONCLUSIONS: Daratumumab may serve as an adjunctive option for refractory AMR with persistent DSAs by targeting plasma cell-mediated alloantibody production. Prospective studies are required to define optimal dosing, timing, safety monitoring, and patient selection.